உலகளாவிய குழந்தை மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உலகளாவிய குழந்தை மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உலகளாவிய குழந்தை மருந்து Today - Breaking & Trending Today

Gene therapy appears more cost effective than current treatments for severe hemophilia B

Date Time
Gene therapy appears more cost effective than current treatments for severe hemophilia B
From left: Co-senior author Nickhill Bhakta, M.D., of St. Jude Global Pediatric Medicine; co-senior author Ulrike Reiss, M.D., of the St. Jude Department of Hematology; and first and corresponding author Nancy Bolous, M.D., of St. Jude Global Pediatric Medicine, provide research on the costs of hemophilia gene therapy now in development.
A St. Jude Children’s Research Hospital analysis found a major gap between the cost to manufacture and distribute hemophilia B gene therapy and the $2 million-plus price reportedly under consideration for hemophilia gene therapy now in development. ....

United States , City Of , United Kingdom , Amit Nathwani , Andrew Davidoff , Yichen Chen , Ellis Neufeld , Meenakshi Devidas , Michael Meagher , Bryan Piras , Huiqi Wang , Nickhill Bhakta , Nancy Bolous , Ulrike Reiss , Timothy Jacobs , Carlos Rodriguez Galindo , Jude Children Research Hospital , Judeglobal Pediatric Medicine Department , Department Of Hematology , University College London Royal Free Hospital , Global Pediatric Medicine , Jude Children , Research Hospital , Judeglobal Pediatric Medicine , Jude Global Pediatric , University College ,

Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma

Date Time
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma
(From left) First and corresponding author Monika Metzger, M.D., Departments of Oncology and Global Pediatric Medicine; co- senior author Matthew Krasin, M.D., Department of Radiation Oncology; and co-senior author Melissa Hudson, M.D., Cancer Survivorship Division director.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a multi-site consortium dedicated to pediatric Hodgkin-lymphoma. Collaborating institutions include St. Jude Children’s Research Hospital, Stanford University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital, Maine Childr ....

United States , Dana Farber Cancer Institute , Belinda Mandrell , Susan Hiniker , Alison Friedmann , John Lucas Jr , Sandra Luna Fineman , Chen Li , Matthew Ehrhardt , Matthew Krasin , Monika Metzger , Nickhill Bhakta , Amy Billett , Melissa Hudson , Hodgkin Reed Sternberg , Zhaohua Lu , Barry Shulkin , Jamie Flerlage , Eric Larson , Nemours Alfredi Dupont , Torunn Yock , Sarah Donaldson , National Cancer Institute , Jude Children Research Hospital , Judecancer Survivorship Division , Stanford University School Of Medicine ,